This trial is testing a new drug (M9241) to see if it is safe and if it can help the immune system to fight prostate cancer.
2 Primary · 1 Secondary · Reporting Duration: four weeks after start of treatment
Experimental Treatment
65 Total Participants · 3 Treatment Groups
Primary Treatment: Stereotactic Body Radiation Therapy (SBRT) · No Placebo Group · Phase 2
Age 18+ · Male Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: